Anti- npra inhibitors targeting cancer stem cells in tumoroids

Ended Definitive Contract Awarded Last action

Contract number
HHSN261201400028C
Awardee
Awarding agency
Obligated
$224,999

Award facts

Opportunity
  • N43CO4100527 Solicitation number
Contract value 100% obligated
$224,999.00 Current and potential, with all options
Completion date 100% complete
Current and potential, with all options
Set-aside
No set-aside
Competition
Full and Open Competition · 27 offers Negotiated Proposal / Quote
Pricing
Firm Fixed Price
Place of performance
Tampa, FL 33613, USA

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Other Administrative Action 1 $0
Original award $224,999

About this award

The National Cancer Institute awarded a $224,999.00 Firm Fixed Price definitive contract to Transgenex Nanobiotech Inc., a minority-owned for-profit business, to develop anti-NPRA inhibitors targeting cancer stem cells in tumoroids. The contract has a completion date of September 11, 2015 and is not associated with any set-aside designation. Transgenex Nanobiotech Inc. has received previous federal contract and grant awards, with the most recent contract award on February 1, 2017.

Quick answers

Who was awarded contract HHSN261201400028C?

HHSN261201400028C was awarded to Transgenex Nanobiotech Inc. by National Cancer Institute (National Institutes of Health) on September 12, 2014.

How much is contract HHSN261201400028C worth?

The government has obligated $224,999 on HHSN261201400028C.

Was contract HHSN261201400028C competed?

The extent of competition for HHSN261201400028C was full and open competition. The government received 27 offers.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award